| Identification | Back Directory | [Name]
(R)-BUTAPROST | [CAS]
69685-22-9 | [Synonyms]
TR 4978
TR 4979
BUTAPROST
(R)-BUTAPROST
Butaprost Exclusive
XRISENIKJUKIHD-IOOSKWMSSA-N
(+/-)-15-DEOXY-16S-HYDROXY-17-CYCLOBUTYL PROSTAGLANDIN E1 METHYL ESTER
(+/-)-15-DEOXY-16R-HYDROXY-17-CYCLOBUTYL PROSTAGLANDIN E1 METHYL ESTER
9-OXO-11ALPHA, 16R-DIHYDROXY-17-CYCLOBUTYL-PROST-13E-EN-1-OIC ACID, METHYL ESTER
9-OXO-11ALPHA, 16S-DIHYDROXY-17-CYCLOBUTYL-PROST-13E-EN-1-OIC ACID, METHYL ESTER
(1R,2R,3R)-3-HYDROXY-2-[(1E,4R)-4-HYDROXY-4-(1-PROPYLCYCLOBUTYL)-1-BUTENYL]-5-OXO-CYCLOPENTANEHEPTANOIC ACID METHYL ESTER | [Molecular Formula]
C24H40O5 | [MDL Number]
MFCD00867055 | [MOL File]
69685-22-9.mol | [Molecular Weight]
408.57 |
| Chemical Properties | Back Directory | [Boiling point ]
525.1±50.0 °C(Predicted) | [density ]
1.105±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C | [solubility ]
DMSO: freely soluble | [form ]
oil | [pka]
13.89±0.60(Predicted) | [color ]
light yellow |
| Hazard Information | Back Directory | [Uses]
Bronchodilator. | [in vivo]
Butaprost (1-4 mg/kg; intraperitoneal injection; twice daily; for 7 days) treatment attenuates the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery, as illustrated by a reduction in the gene and protein expression of α-smooth muscle actin, fibronectin and collagen 1A1[2]. | Animal Model: | Male C57BL/6 mice (8 weeks of age; 21 g) bearing unilateral ureteral obstruction surgery[2] | | Dosage: | 1 mg/kg, 2 mg/kg, 4 mg/kg | | Administration: | Intraperitoneal injection; twice daily; for 7 days | | Result: | Attenuated the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery. |
|
|
| Company Name: |
amyjetsci
|
| Tel: |
027-59626688 18771149750 |
| Website: |
https://www.amyjet.com/ |
|